Sanofi (ETR:SNW)
Germany
· Delayed Price · Currency is EUR 82.42
-0.26 (-0.31%)
Jun 27, 2025, 5:35 PM CET
Sanofi Revenue
Sanofi had revenue of 10.61B EUR in the quarter ending March 31, 2025, a decrease of -4.61%. This brings the company's revenue in the last twelve months to 45.17B, down -2.42% year-over-year. In the year 2024, Sanofi had annual revenue of 44.29B with 7.73% growth.
Revenue (ttm)
45.17B
Revenue Growth
-2.42%
P/S Ratio
2.22
Revenue / Employee
544.97K
Employees
82,878
Market Cap
100.49B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 44.29B | 3.18B | 7.73% |
| Dec 31, 2023 | 41.11B | 805.00M | 2.00% |
| Dec 31, 2022 | 40.30B | 1.13B | 2.88% |
| Dec 31, 2021 | 39.18B | 1.81B | 4.83% |
| Dec 31, 2020 | 37.37B | -262.00M | -0.70% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Siemens Healthineers AG | 23.14B |
| Merck KGaA | 21.32B |
| Bayer Aktiengesellschaft | 46.58B |
| Fresenius SE & Co. KGaA | 22.13B |
| Sartorius Aktiengesellschaft | 3.44B |
| Fresenius Medical Care AG | 19.49B |
| Carl Zeiss Meditec AG | 2.17B |
| Fielmann Group AG | 2.33B |
Sanofi News
- 2 days ago - Sanofi awards Healthy Futures Solution Fund grants to advance community-led solutions, expand equitable access to care across Massachusetts - PRNewsWire
- 3 days ago - Press Release: Riliprubart earns orphan drug designation in the US for antibody-mediated rejection in solid organ transplantation - GlobeNewsWire
- 3 days ago - Nektar Therapeutics Shares Double On Promising Eczema Drug Data - Benzinga
- 4 days ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY - GlobeNewsWire
- 5 days ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY - PRNewsWire
- 7 days ago - BLUEPRINT MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Blueprint Medicines Corporation - BPMC - Business Wire
- 8 days ago - Regeneron, Sanofi win FDA label expansion for Dupixent against rare skin disorder - Seeking Alpha
- 8 days ago - Sanofi, Regeneron Get FDA Approval for Dupixent to Treat Rare Skin Disease - WSJ